The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following are excluded:
• •History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction and severe gastric ulcer.
• •Lymphoid malignancy.
• •Infectious mononucleosis caused by cytomegalovirus or Epstein-Barr virus.
• •Heart disease (especially if receiving cardiac glycosides).
• •Hemophilia.
• •Patients with the following are excluded:
• •Kaposi's sarcoma or overt opportunistic infections as follows:
• •Candida albicans, Pneumocystis carinii, Herpes simplex, Cryptococcus neoformans, Histoplasma capsulatum, Mycobacterium avium-intracellulare, Toxoplasma gondii, Legionella, Cryptosporidium, Isospora, and Papovavirus.
• •Active evidence of infectious mononucleosis caused by Epstein-Barr virus (EBV) or cytomegalovirus (CMV) as determined by heterophil test (EBV) or cell culture (CMV).
• •History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer.
• •Critical illness.
• •Condition requiring hospitalization.
• •Women of childbearing age are excluded.
• •Hemophilia.
• •Prior Medication:
• •Excluded:
• •Steroids.
• •Cytotoxic immunosuppressive agents.
• •Antiviral medicine.
• •Prior Treatment:
• •Excluded:
• •Radiotherapy.
• •Patients who have unexplained immunodepression and are at risk of developing AIDS.
• •Patients with prolonged generalized lymphadenopathy for 3 or more months (greater than 1 cm at two or more noncontiguous sites).
• •IV drug abuse.